Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 44

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 44
---
 are shareholders of MIRALOGIX, the licensor to SKNY of certain of SKNY’s product candidates. In some cases, such licenses obligate SKNY to pay royalties to MIRALOGIX even if SKNY is not then earning revenue on the licensed products.

The members of the MIRA Board were aware of and considered these interests in evaluating the Merger and in making the MIRA Recommendation. The interests of MIRA’s directors and executive officers are described in more detail in “ Interests of the MIRA Directors, Executive Officers and Affiliate Shareholders in the Merger”on page 31 of this proxy statement.

The completion of the Merger is not conditioned on the receipt of an opinion of counsel to the effect that the Merger will qualify for the Intended Tax Treatment, and neither MIRA nor SKNY intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger.

It is intended that, for U.S. federal income tax purposes, the Merger will constitute the Intended Tax Treatment (as defined below). However, the completion of the Merger is not conditioned on the Merger qualifying for the Intended Tax Treatment or upon the receipt of an opinion from counsel to that effect, and whether or not the Transaction will qualify for the Intended Tax Treatment depends on facts that will not be known until the Merger is completed. Finally, neither MIRA nor SKNY intends to request a ruling from the Internal Revenue Service regarding the U.S. federal income tax consequences of the Merger. Therefore, even if MIRA concludes that the Merger qualifies for the Intended Tax Treatment, no assurance can be given that the Internal Revenue Service will not challenge that conclusion or that a court would not sustain such a challenge.

| 21 |

You should read “ Material U.S. Federal Income Tax Considerations” and consult your own tax advisors regarding the U.S. federal income tax consequences of the Merger to you in your particular circumstances.

MIRA is subject to various uncertainties, including contractual restrictions and requirements while the Merger is pending, that could adversely affect their businesses, financial condition and results of operations.

During the pendency of the Merger, it is possible that commercial partners and/or other persons with whom MIRA has a business relationship may elect to delay or defer certain business decisions or seek to terminate, change or renegotiate their relationships with MIRA as a result of the Merger. Such events and actions could significantly reduce the expected benefits of the Mer